Octapharma USA's Kerem Tokel explains how tariffs and DSCSA are affecting how stolen pharma loads are resold, and why partner SOPs matter.
Commentary|Podcasts|November 27, 2024
Nov. 27 is Here: What Does That Mean for DSCSA?
Author(s)Nicholas Saraceno, Senior Editor
Nicholas Saraceno offers an overview of the legislation and how it impacts the pharma supply chain.
Advertisement
In this episode of The PC Podcast, Nicholas Saraceno, Pharma Commerce’s editor, explains:
- The history behind the Drug Supply Chain Security Act (DSCSA)
- The significance of Nov. 27
- The latest DSCSA exemptions and what that means for trading partners
- How this piece of legislation and AI are able to intertwine
The latest episode of The Pharmaceutical Commerce Podcast is available directly on
Advertisement
Related to this article
In this week's Pharma Pulse, PhRMA sues to block CMS's GLOBE pricing model, WFS opens a temperature-controlled cargo terminal in Lyon and Bayer commits $2.2 billion to a new Ohio manufacturing site.
In this week's Pharma Pulse, the EU Council adopts the "pharma package," Commerce details 0% tariffs for certain drugs and Sharp expands autoinjector assembly capacity.
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
In this week's Pharma Pulse, Arkansas independent pharmacies bring an underpayment suit against Express Scripts, Novo Nordisk taps Anthropic for AI-driven drug discovery, and Sanofi, UCB and Opella join AstraZeneca on a supply chain heat decarbonization program.
DSCSA data exchange has matured into daily operations, but the coming NDC-12 shift and a national licensure standard add new work streams before old ones are fully settled.
Go behind the scenes of LogiPharma USA 2026 with program director Charleen Ring and McKesson's Chris Van Norman in this Pharma Pulse special.
At LogiPharma USA 2026, Cold Chain Technologies' TJ Rizzo explains how gaps in end-to-end cold chain expertise create risk for advanced therapies.
Advertisement
Advertisement